litlas
ログインアカウント作成

Jeffrey S. Chamberlain

1977–2025 年に発表

119
論文数
20,613
被引用数
86
h 指数
115
i10 指数

被引用数

Jeffrey S. Chamberlain の年別被引用数1978 年: 被引用 2 件1986 年: 被引用 2 件1987 年: 被引用 5 件1988 年: 被引用 22 件1989 年: 被引用 51 件1990 年: 被引用 48 件1991 年: 被引用 68 件1992 年: 被引用 47 件1993 年: 被引用 79 件1994 年: 被引用 63 件1995 年: 被引用 55 件1996 年: 被引用 114 件1997 年: 被引用 87 件1998 年: 被引用 71 件1999 年: 被引用 107 件2000 年: 被引用 146 件2001 年: 被引用 97 件2002 年: 被引用 188 件2003 年: 被引用 116 件2004 年: 被引用 171 件2005 年: 被引用 159 件2006 年: 被引用 202 件2007 年: 被引用 159 件2008 年: 被引用 252 件2009 年: 被引用 171 件2010 年: 被引用 242 件2011 年: 被引用 188 件2012 年: 被引用 177 件2013 年: 被引用 122 件2014 年: 被引用 123 件2015 年: 被引用 177 件2016 年: 被引用 99 件2017 年: 被引用 133 件2018 年: 被引用 120 件2019 年: 被引用 460 件2020 年: 被引用 458 件2021 年: 被引用 445 件2022 年: 被引用 303 件2023 年: 被引用 310 件2024 年: 被引用 386 件2025 年: 被引用 257 件2026 年: 被引用 4 件1979〜1985 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,147 件、この内訳の 37.6%イギリス: 引用元論文 500 件、この内訳の 8.8%イタリア: 引用元論文 307 件、この内訳の 5.4%フランス: 引用元論文 294 件、この内訳の 5.2%中国: 引用元論文 289 件、この内訳の 5.1%カナダ: 引用元論文 236 件、この内訳の 4.1%ドイツ: 引用元論文 236 件、この内訳の 4.1%オーストラリア: 引用元論文 209 件、この内訳の 3.7%日本: 引用元論文 196 件、この内訳の 3.4%オランダ: 引用元論文 144 件、この内訳の 2.5%スペイン: 引用元論文 87 件、この内訳の 1.5%スウェーデン: 引用元論文 84 件、この内訳の 1.5%
0%37.6%その他 17.1%

機関

分野

  • Biochemistry, Genetics and Molecular Biology76.7%
  • Medicine16.8%
  • Neuroscience2.3%
  • Immunology and Microbiology1.2%
  • Agricultural and Biological Sciences0.9%
  • Engineering0.9%
  • その他1.2%

トピック

  • Muscle Physiology and Disorders16.3%
  • Virus-based gene therapy research7%
  • CRISPR and Genetic Engineering6.3%
  • Cardiomyopathy and Myosin Studies3.5%
  • RNA Interference and Gene Delivery3.2%
  • Adipose Tissue and Metabolism3.2%
  • その他60.5%

共著者

全論文

検索で開く
  1. High levels of AAV vector integration into CRISPR-induced DNA breaks

    著者: Killian S. Hanlon, Benjamin P. Kleinstiver, Sara P. Garcia, Mikołaj Piotr Zaborowski, Adrienn Volak, Stefan E. Spirig, Alissa Muller, Alexander A. Sousa, Shengdar Q. Tsai, Niclas E. Bengtsson, Camilla Lööv, Martin Ingelsson, Jeffrey S. Chamberlain, David P. Corey, Martin J. Aryee, J. Keith Joung, Xandra O. Breakefield, Casey A. Maguire, Bence György - Nature Communications 2019 被引用: 432

  2. Cas9 immunity creates challenges for CRISPR gene editing therapies

    著者: Julie M. Crudele, Jeffrey S. Chamberlain - Nature Communications 2018 被引用: 251

  3. Design of Tissue-specific Regulatory Cassettes for High-level rAAV-mediated Expression in Skeletal and Cardiac Muscle

    著者: Maja Z. Salva, Charis L. Himeda, Phillip W.L. Tai, Eiko Nishiuchi, Paul Gregorevic, James M. Allen, Eric Finn, Quynh G Nguyen, Michael J. Blankinship, Leonard Meuse, Jeffrey S. Chamberlain, Stephen D. Hauschka - Molecular Therapy 2007 被引用: 226

  4. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy

    著者: Niclas E. Bengtsson, John K. Hall, Guy L. Odom, Michael Phelps, Colin Andrus, R. David Hawkins, Stephen D. Hauschka, Joel R. Chamberlain, Jeffrey S. Chamberlain, Jeffrey S. Chamberlain, Jeffrey S. Chamberlain - Nature Communications 2017 被引用: 384

  5. Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin

    著者: Catherine E. Winbanks, Kate L. Weeks, Rachel E. Thomson, Patricio V. Sepulveda, Claudia Beyer, Hongwei Qian, Justin L. Chen, James M. Allen, Graeme I. Lancaster, Mark A. Febbraio, Craig A. Harrison, Julie R. McMullen, Jeffrey S. Chamberlain, Paul Gregorevic - The Journal of Cell Biology 2012 被引用: 214

  6. Split intein-mediated protein trans-splicing to express large dystrophins

    著者: Hichem Tasfaout, Christine L. Halbert, Timothy S. McMillen, James M. Allen, Theodore R. Reyes, Galina Flint, Dirk Grimm, Stephen D. Hauschka, Michael Regnier, Jeffrey S. Chamberlain - Nature 2024 被引用: 59

  7. Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy

    著者: Sharla M. Birch, Michael W. Lawlor, Thomas J. Conlon, Lee‐Jae Guo, Julie M. Crudele, Eleanor C. Hawkins, Peter P. Nghiem, Mihye Ahn, Hui Meng, Margaret Beatka, Brittany A. Fickau, Juan Carlos Prieto, Martin Styner, Michael J. Struharik, Courtney Shanks, Kristy J. Brown, Diane Golebiowski, Amanda K. Bettis, Cynthia Balog-Alvarez, Nathalie Clément, Kirsten E. Coleman, Manuela Corti, Xiufang Pan, Stephen D. Hauschka, J. Patrick Gonzalez, Carl Morris, Joel Schneider, Dongsheng Duan, Jeffrey S. Chamberlain, Barry J. Byrne, Joe N. Kornegay - Science Translational Medicine 2023 被引用: 68

  8. Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy

    著者: Scott Q. Harper, Michael A. Hauser, Christiana DelloRusso, Dongsheng Duan, Robert W. Crawford, Stephanie F. Phelps, Hollie A. Harper, Ann S. Robinson, John F. Engelhardt, Susan V. Brooks, Jeffrey S. Chamberlain - Nature Medicine 2002 被引用: 561

  9. Systemic delivery of genes to striated muscles using adeno-associated viral vectors

    著者: Paul Gregorevic, Michael J. Blankinship, James M. Allen, Robert W. Crawford, Leonard Meuse, Daniel G. Miller, David W. Russell, Jeffrey S. Chamberlain - Nature Medicine 2004 被引用: 611

  10. Enveloped viruses pseudotyped with mammalian myogenic cell fusogens target skeletal muscle for gene delivery

    著者: Sajedah M. Hindi, Michael J. Petrany, Elena Greenfeld, Leah C. Focke, A. Cramer, Michael A. Whitt, Ramzi J. Khairallah, Christopher W. Ward, Jeffrey S. Chamberlain, Vikram Prasad, Benjamin Podbilewicz, Douglas P. Millay - Cell 2023 被引用: 34

  11. AAV-based gene therapies for the muscular dystrophies

    著者: Julie M. Crudele, Jeffrey S. Chamberlain - Human Molecular Genetics 2019 被引用: 118

  12. Development of Novel Micro-dystrophins with Enhanced Functionality

    著者: Julian N. Ramos, Katrin Hollinger, Niclas E. Bengtsson, J. M. Allen, Stephen D. Hauschka, Jeffrey S. Chamberlain - Molecular Therapy 2019 被引用: 114

  13. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy

    著者: Yi Lai, Gail D. Thomas, Yongping Yue, H. T. Yang, Dejia Li, Chun Long, Luke M. Judge, Brian Bostick, Jeffrey S. Chamberlain, Ronald L. Terjung, Dongsheng Duan - Journal of Clinical Investigation 2009 被引用: 380

  14. Progress toward Gene Therapy for Duchenne Muscular Dystrophy

    著者: Joel R. Chamberlain, Joel R. Chamberlain, Jeffrey S. Chamberlain, Jeffrey S. Chamberlain - Molecular Therapy 2017 被引用: 222

  15. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors

    著者: Yi Lai, Yongping Yue, Mingju Liu, Arkasubhra Ghosh, John F. Engelhardt, Jeffrey S. Chamberlain, Dongsheng Duan - Nature Biotechnology 2005 被引用: 216

  16. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification

    著者: Jeffrey S. Chamberlain, Richard A. Gibbs, Joel E. Rainer, Phi Nga Nguyen, Christopher D. Thomas - Nucleic Acids Research 1988 被引用: 1,268

  17. Dystrophin‐deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma

    著者: Jeffrey S. Chamberlain, Joseph M. Metzger, Morayma Reyes, DeWayne Townsend, John A. Faulkner - The FASEB Journal 2007 被引用: 322

  18. Skeletal Muscle Contractions Induce Acute Changes in Cytosolic Superoxide, but Slower Responses in Mitochondrial Superoxide and Cellular Hydrogen Peroxide

    著者: Tim Pearson, Tabitha Kabayo, Rainer Ng, Jeffrey S. Chamberlain, Anne McArdle, Malcolm J. Jackson - PLoS ONE 2014 被引用: 106

  19. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells

    著者: Arianna Dellavalle, Maurilio Sampaolesi, Rossana Tonlorenzi, Enrico Tagliafico, Benedetto Sacchetti, Laura Perani, A Innocenzi, Beatriz G. Gálvez, Graziella Messina, Roberta Morosetti, Sheng Li, M. Belicchi, Giuseppe M. Peretti, Jeffrey S. Chamberlain, Woodring E. Wright, Yvan Torrente, Stefano Ferrari, Paolo Bianco, Giulio Cossu - Nature Cell Biology 2007 被引用: 974

  20. Recombinant Adeno-associated Virus Transduction and Integration

    著者: Brian Schultz, Jeffrey S. Chamberlain - Molecular Therapy 2008 被引用: 208

  21. PCYT2-regulated lipid biosynthesis is critical to muscle health and ageing

    著者: Domagoj Cikes, Kareem Elsayad, Erdinç Sezgin, Erika Koitai, Ferenc Torma, Michael Orthofer, Rebecca Yarwood, Leonhard X. Heinz, Vitaly Sedlyarov, N. Darwish, Adrian Taylor, Sophie Grapentine, Fathiya Al-Murshedi, Anne Abot, Adelheid Weidinger, Candice Kutchukian, Colline Sanchez, Shane J. F. Cronin, Maria Novatchkova, Anoop Kavirayani, Thomas Schuetz, Bernhard J. Haubner, Lisa Haas, Astrid Hagelkrüys, Suzanne Jackowski, Andrey V. Kozlov, Vincent Jacquemond, Claude Knauf, Giulio Superti‐Furga, Eric Rullman, Thomas Gustafsson, John McDermot, Martin Lowe, Zsolt Radák, Jeffrey S. Chamberlain, Marica Bakovic, Siddharth Banka, Josef Penninger - Nature Metabolism 2023 被引用: 57

  22. Microdystrophin Expression as a Surrogate Endpoint for Duchenne Muscular Dystrophy Clinical Trials

    著者: Jeffrey S. Chamberlain, Melissa A. Robb, Serge Braun, Kristy J. Brown, Olivier Danos, Annie Ganot, Pedro Gonzalez‐Alegre, Nina Hunter, Craig M. McDonald, Carl Morris, Mark Tobolowsky, Kathryn R. Wagner, Olivia Ziolkowski, Dongsheng Duan - Human Gene Therapy 2023 被引用: 33

  23. Innate and adaptive AAV-mediated immune responses in a mouse model of Duchenne muscular dystrophy

    著者: Michael R. Emami, Alejandro Espinoza, Courtney S. Young, Feiyang Ma, Philip K. Farahat, Philip L. Felgner, Jeffrey S. Chamberlain, Xiangmin Xu, April D. Pyle, Matteo Pellegrini, S. Armando Villalta, Melissa J. Spencer - Molecular Therapy — Methods & Clinical Development 2023 被引用: 21

  24. Characterization of Dystrophin in Muscle-Biopsy Specimens from Patients with Duchenne's or Becker's Muscular Dystrophy

    著者: Eric P. Hoffman, Kenneth H. Fischbeck, Robert H. Brown, Margaret A. Johnson, Rosella Medori, John D. Loire, John B. Harris, R Waterston, Michael H. Brooke, Linda A. Specht, William J. Kupsky, Jeffrey S. Chamberlain, C. Thomas Caskey, Frederic Shapiro, Louis M. Kunkel - New England Journal of Medicine 1988 被引用: 927